Crescent Biopharma, Inc.

NASDAQ:CBIO USA Biotechnology
Market Cap
$216.45 Million
Market Cap Rank
#40962 Global
#13289 in USA
Share Price
$11.10
Change (1 day)
-4.15%
52-Week Range
$8.94 - $18.00
All Time High
$18.00
About

Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates. Its pipeline includes CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics, inc… Read more

Market Cap & Net Worth: Crescent Biopharma, Inc. (CBIO)

Crescent Biopharma, Inc. (NASDAQ:CBIO) has a market capitalization of $216.45 Million ($216.45 Million) as of March 19, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #40962 globally and #13289 in its home market, demonstrating a -7.65% decrease in market value over the past year.

Market capitalization, also known as net worth in stock markets, is calculated by multiplying Crescent Biopharma, Inc.'s stock price $11.10 by its total outstanding shares 19500000 (19.50 Million).

Crescent Biopharma, Inc. Market Cap History: 2025 to 2026

Crescent Biopharma, Inc.'s market capitalization history from 2025 to 2026. Data shows growth from $231.27 Million to $216.45 Million (0.00% CAGR).

Crescent Biopharma, Inc. Market Cap to Earnings & Revenue Ratios Timeline

This chart shows how Crescent Biopharma, Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.

Latest Price to Sales (P/S) Ratio

No P/S ratio data available

Latest Price to Earnings (P/E) Ratio

No P/E ratio data available

What These Ratios Tell Investors:
  • Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
  • Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
  • Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
  • Industry comparison provides context for whether the company is valued higher or lower than peers.
Year Market Cap (USD) Revenue (USD) Net Income (USD) P/S Ratio P/E Ratio
No financial ratio data available

Competitor Companies of CBIO by Market Capitalization

Companies near Crescent Biopharma, Inc. in the global market cap rankings as of March 19, 2026.

Key companies related to Crescent Biopharma, Inc. by market ranking:

  • Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
  • Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
  • CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
  • argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.

Market capitalization comparison (in billions USD)
Rank Company Symbol Market Cap Price
#162 Vertex Pharmaceuticals Inc NASDAQ:VRTX $117.09 Billion $462.49
#281 Regeneron Pharmaceuticals Inc NASDAQ:REGN $74.80 Billion $759.05
#344 CSL Limited PINK:CMXHF $63.46 Billion $149.87
#500 argenx SE OTCGREY:ARGNF $42.99 Billion $697.42

Crescent Biopharma, Inc. Historical Marketcap From 2025 to 2026

Between 2025 and today, Crescent Biopharma, Inc.'s market cap moved from $231.27 Million to $ 216.45 Million, with a yearly change of 0.00%.

Year Market Cap Change (%)
2026 $216.45 Million -6.41%
2025 $231.27 Million --

End of Day Market Cap According to Different Sources

On Mar 18th, 2026 the market cap of Crescent Biopharma, Inc. was reported to be:

Source Market Cap
Yahoo Finance $216.45 Million USD
MoneyControl $216.45 Million USD
MarketWatch $216.45 Million USD
marketcap.company $216.45 Million USD
Reuters $216.45 Million USD

Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.